Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Hetero Drugs Limited is a global pharmaceutical company that specializes in the development, manufacturing, and marketing of generic medicines and active pharmaceutical ingredients. It provides a diverse range of products across therapeutic segments, including oncology, cardiovascular, anti-diabetic, and antiviral, addressing critical healthcare needs and improving patient outcomes worldwide.
Hetero Drugs Limited, is an unlisted public company incorporated on 06 April, 1993. It is classified as a public limited company and is located in Hyderabad, Telangana. It's authorized share capital is INR 10.00 cr and the total paid-up capital is INR 3.45 cr.
Read more
** All rupee values in INR crores. Based on March 2025 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Adi Sesha Giri Jagarapu | 08774486 | 5 years |
| Director | Kalavathi Bandi
Shareholder
|
00194597 | 11 years |
| Director | Venkatanarasa Reddy Attunuri
Shareholder
|
00023432 | 28 years |
| Whole-time director | Sambi Reddy Jonnala
Shareholder
|
00211459 | 14 years |
| Director | Parthasaradhi Reddy Bandi
Shareholder
|
00015899 | 9 years |
| Director | Bandi Vamsikrishna
Shareholder
|
01014619 | 18 years |
| Director | Gopal Reddy Annareddy | 07306495 | 3 years |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | 2,403.4 | 2,456.3 | 2,936.4 | 2,846.4 | 3,208.8 |
| Operating profit | 341.8 | 241.0 | 272.6 | 265.2 | 278.1 |
| Net profit | 223.4 | 99.9 | 164.9 | 89.6 | 235.7 |
| Gross margin | 34.5 | 32.9 | 31.0 | 32.1 | 31.8 |
| Operating margin | 14.2 | 9.8 | 9.3 | 9.3 | 8.7 |
| Net margin | 9.1 | 4.0 | 5.5 | 3.1 | 7.2 |
| Networth | 1,836.5 | 2,013.0 | 2,175.0 | 2,262.3 | 2,495.7 |
| Borrowings | 244.5 | 392.6 | 399.4 | 590.5 | 435.6 |
| Assets | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 | 3,811.7 |
| Debt to equity | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 |
| Current ratio | 2.1 | 1.9 | 2.0 | 1.9 | 2.3 |
| ROE | 12.2 | 5.0 | 7.6 | 4.0 | 9.4 |
| Days payable | 112.0 | 122.0 | 114.0 | 112.0 | 110.0 |
| WC days | 124.0 | 132.0 | 131.0 | 137.0 | 159.0 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 |
| Reserves | 1,833.1 | 2,009.6 | 2,171.6 | 2,258.8 | 2,492.3 |
| Borrowings + | 244.5 | 392.6 | 399.4 | 590.5 | 435.6 |
| Long term borrowings | 32.4 | 4.1 | 2.9 | 13.0 | 26.8 |
| Short term borrowings | 212.1 | 388.5 | 396.5 | 577.5 | 408.8 |
| Trade payables + | 482.4 | 552.7 | 632.4 | 590.6 | 662.0 |
| Days payable | 112.0 | 122.0 | 114.0 | 112.0 | 110.0 |
| Other liabilities + | 213.3 | 170.8 | 191.9 | 212.3 | 218.4 |
| Other non-current liabilities | 132.9 | 133.9 | 148.0 | 180.5 | 188.2 |
| Other current liabilities | 80.4 | 37.0 | 44.0 | 31.8 | 30.2 |
| Total liabilities | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 | 3,811.7 |
| Fixed Assets + | 633.1 | 686.9 | 717.4 | 824.8 | 908.2 |
| Tangible assets | 551.4 | 607.7 | 627.2 | 687.1 | 781.9 |
| CWIP | 22.0 | 19.8 | 27.7 | 43.0 | 41.0 |
| Intangible assets | 59.7 | 59.5 | 62.5 | 94.7 | 85.4 |
| LT loans and advances | 149.2 | 74.7 | 54.9 | 66.6 | 83.1 |
| Other non-current assets | 401.2 | 499.9 | 497.4 | 492.8 | 318.7 |
| Current assets + | 1,593.3 | 1,867.7 | 2,129.1 | 2,271.4 | 2,501.6 |
| Inventories | 575.0 | 826.6 | 1,023.6 | 1,111.0 | 999.1 |
| Trade receivables | 843.5 | 819.0 | 864.4 | 937.5 | 1,302.0 |
| Cash and cash equivalents | 18.1 | 9.7 | 21.0 | 21.9 | 20.7 |
| ST loans and advances | 72.9 | 45.4 | 29.4 | 29.2 | 5.9 |
| Other current assets | 83.9 | 166.9 | 190.7 | 171.9 | 173.9 |
| Total assets | 2,776.8 | 3,129.2 | 3,398.8 | 3,655.7 | 3,811.7 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales + | 2,403.4 | 2,456.3 | 2,936.4 | 2,846.4 | 3,208.8 |
| Sales growth % | 30.44 | 2.2 | 19.54 | -3.06 | 12.73 |
| Expenses + | 2,143.3 | 2,292.2 | 2,766.2 | 2,702.0 | 3,070.5 |
| Cost of goods | 1,574.6 | 1,648.2 | 2,027.3 | 1,931.9 | 2,190.1 |
| Employee cost | 143.7 | 172.1 | 190.7 | 202.5 | 234.8 |
| Other costs | 343.4 | 395.1 | 445.7 | 446.9 | 505.8 |
| Operating profit + | 341.8 | 241.0 | 272.6 | 265.2 | 278.1 |
| Operating margin % | 14.2 | 9.8 | 9.3 | 9.3 | 8.7 |
| Other income | 39.8 | 52.2 | 67.7 | 26.1 | 45.1 |
| Interest | 30.2 | 23.8 | 45.8 | 54.0 | 64.5 |
| Depreciation | 51.4 | 53.1 | 56.6 | 66.7 | 75.3 |
| Exceptional items | - | - | - | - | 123.9 |
| Profit before tax | 299.9 | 216.3 | 237.9 | 170.6 | 307.3 |
| Tax | 76.6 | 116.4 | 73.0 | 81.0 | 71.6 |
| Profit - disc. ops | - | - | - | - | - |
| Net profit | 223.4 | 99.9 | 164.9 | 89.6 | 235.7 |
| Net margin % | 9.1 | 4.0 | 5.5 | 3.1 | 7.2 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 |
| Net Debt/Equity | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 |
| Total Debt/Assets | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
| Total Assets/Equity | 1.5 | 1.6 | 1.6 | 1.6 | 1.5 |
| Liquidity + | |||||
| Current Ratio | 2.1 | 1.9 | 2.0 | 1.9 | 2.3 |
| Quick Ratio | 1.3 | 1.1 | 1.0 | 1.0 | 1.4 |
| Interest Coverage | 11.3 | 10.1 | 6.0 | 4.9 | 4.3 |
| Performance | |||||
| Gross Margin | 34.5 | 32.9 | 31.0 | 32.1 | 31.8 |
| Operating Margin | 14.2 | 9.8 | 9.3 | 9.3 | 8.7 |
| Net Margin | 9.1 | 4.0 | 5.5 | 3.1 | 7.2 |
| Return + | |||||
| Return on Equity | 12.2 | 5.0 | 7.6 | 4.0 | 9.4 |
| Pre-tax ROCE | 20.0 | 11.9 | 12.2 | 10.5 | 8.8 |
| Return on Assets | 8.0 | 3.2 | 4.8 | 2.5 | 6.2 |
| Pre-tax ROIC | 14.1 | 7.8 | 8.5 | 7.0 | 7.0 |
| Efficiency + | |||||
| Days Payable | 112.0 | 122.0 | 114.0 | 112.0 | 110.0 |
| Days Inventory | 133.0 | 183.0 | 184.0 | 210.0 | 167.0 |
| Days Receivable | 128.0 | 122.0 | 107.0 | 120.0 | 148.0 |
| Fixed Asset Turnover | 3.8 | 3.6 | 4.1 | 3.5 | 3.5 |
| Total Asset Turnover | 0.9 | 0.8 | 0.9 | 0.8 | 0.8 |
| Working Capital | |||||
| Cash Conversion Cycle | 149.0 | 183.0 | 177.0 | 218.0 | 205.0 |
| Working Capital Days | 124.0 | 132.0 | 131.0 | 137.0 | 159.0 |
As per information available, the company has no registered charges.
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| HETERO BIOTECH LIMITED | Telangana | 2004 | ₹ 5.0 L |
Read more
The incorporation date of HETERO DRUGS LIMITED is 06 April, 1993
The authorized share capital of HETERO DRUGS LIMITED is INR ₹ 10.0 Cr.
The paid-up capital of HETERO DRUGS LIMITED is INR ₹ 3.5 Cr.
The registered address of HETERO DRUGS LIMITED is #7-2-A2, INDUSTRIAL ESTATE SANATHNAGAR Hyderabad Telangana - 500018
The CIN number of HETERO DRUGS LIMITED is U24230TG1993PLC015582.